Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marek Pruszynski

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Radiopharmaceuticals|December 29, 2011
Astatine-211: production and availabilityMichael R Zalutsky, Marek Pruszynski
Molecular Pharmaceutics|March 6, 2018
Evaluation of an Anti-HER2 Nanobody Labeled with <sup>225</sup>Ac for Targeted α-Particle Therapy of CancerMarek Pruszynski, Matthias D'Huyvetter, Frank Bruchertseifer, et al.
Nuclear Medicine and Biology|September 22, 2014
D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodinationMarek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, et al.
Molecules (Basel, Switzerland)|May 23, 2018
d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate SubstitutionMarek Pruszynski, Choong Mo Kang, Eftychia Koumarianou, et al.
Organic & Biomolecular Chemistry|December 10, 2015
N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomoleculesGanesan Vaidyanathan, Darryl McDougald, Jaeyeon Choi, et al.
Nuclear Medicine and Biology|November 20, 2012
Targeting breast carcinoma with radioiodinated anti-HER2 NanobodyMarek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, et al.
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|March 27, 2018
Functionalized TiO<sub>2</sub> nanoparticles labelled with <sup>225</sup>Ac for targeted alpha radionuclide therapyEdyta Cędrowska, Marek Pruszynski, Agnieszka Majkowska-Pilip, et al.
Nuclear Medicine and Biology|April 30, 2014
Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeuticEftychia Koumarianou, Tatiana A Slastnikova, Marek Pruszynski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 2014
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabelingMarek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, et al.
Nuclear Medicine and Biology|August 27, 2014
N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualizationJaeyeon Choi, Ganesan Vaidyanathan, Eftychia Koumarianou, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Radiopharmaceuticals|December 29, 2011
Astatine-211: production and availabilityMichael R Zalutsky, Marek Pruszynski
Molecular Pharmaceutics|March 6, 2018
Evaluation of an Anti-HER2 Nanobody Labeled with <sup>225</sup>Ac for Targeted α-Particle Therapy of CancerMarek Pruszynski, Matthias D'Huyvetter, Frank Bruchertseifer, et al.
Nuclear Medicine and Biology|September 22, 2014
D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodinationMarek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, et al.
Molecules (Basel, Switzerland)|May 23, 2018
d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate SubstitutionMarek Pruszynski, Choong Mo Kang, Eftychia Koumarianou, et al.
Organic & Biomolecular Chemistry|December 10, 2015
N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomoleculesGanesan Vaidyanathan, Darryl McDougald, Jaeyeon Choi, et al.
Nuclear Medicine and Biology|November 20, 2012
Targeting breast carcinoma with radioiodinated anti-HER2 NanobodyMarek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, et al.
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|March 27, 2018
Functionalized TiO<sub>2</sub> nanoparticles labelled with <sup>225</sup>Ac for targeted alpha radionuclide therapyEdyta Cędrowska, Marek Pruszynski, Agnieszka Majkowska-Pilip, et al.
Nuclear Medicine and Biology|April 30, 2014
Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeuticEftychia Koumarianou, Tatiana A Slastnikova, Marek Pruszynski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 2014
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabelingMarek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, et al.
Nuclear Medicine and Biology|August 27, 2014
N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualizationJaeyeon Choi, Ganesan Vaidyanathan, Eftychia Koumarianou, et al.
Pageof 2